Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2402)	6/8/2010 10:16:09 AM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

PPCO was up 21.22% and is still up 16.19% <g> Volume is > 3x its ADV. bigcharts.marketwatch.com It announced today together with ENDO it has settled litigation with Sandoz regarding the production and sale of generic formulations of OPANA Extended Release tablets. Under the terms of the settlement, ENDO & PPCO agreed to grant Sandoz a license to sell a generic of OPANA on Sept2012. The ACTAY is $4 PPCO has 4Qs of better revenues and earnings. The EE for 2010 & 2011 are around $0.85 & $1.10 vs. loss of $0.04 in 2009. The stock has a good amount of resistance at the $3.50 level. bigcharts.marketwatch.com But if it can go over that hurdle, it seems that it could still double from present levels.<g> bigcharts.marketwatch.com Bernard